BusinessBusinessPfizer

Pfizer Delays Generic Lipitor Release Until 2011

Pfizer Delays Generic Lipitor Release Until 2011
By 

Contributor

|
Open Image Modal

Pfizer Inc. and India's Ranbaxy Laboratories Ltd. agreed to keep copies of the cholesterol pill Lipitor off the U.S. market an extra 20 months, a move that may generate an added $12 billion for the U.S. drugmaker.

Under a lawsuit settlement, Ranbaxy won't sell generic versions of Lipitor, the world's best-selling drug, until November 2011, New York-based Pfizer said today in a statement. Analysts had projected Ranbaxy would enter the market in March 2010, when the main patent expires, while Pfizer was using litigation to delay competition until 2016.

Read more on Bloomberg

Our 2024 Coverage Needs You

As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.

Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.

to keep our news free for all.

Support HuffPost
Suggest a correction
|
Submit a tip